(Q37844327)

24 August 2017

1 reference

title

Sink hypothesis and therapeutic strategies for attenuating Abeta levels (English)

1 reference

24 August 2017

Yan Zhang

1

1 reference

24 August 2017

Daniel H S Lee

series ordinal

2

1 reference

24 August 2017

language of work or name

1 reference

16 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

17

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

163-173

1 reference

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Inhibition of the brain to blood transport system for enkephalins and Tyr-MIF-1 in mice addicted or genetically predisposed to drinking ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Leptin enters the brain by a saturable system independent of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Interactions of beta-amyloids with the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Laminar specific loss of isocortical presenilin 1 immunoreactivity in Alzheimer's disease. Correlations with the amyloid load and the density of tau-positive neurofibrillary tangles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Amyloidosis and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Peptidases, proteases and amyloid beta-peptide catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Neprilysin and amyloid beta peptide degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

The role of apolipoprotein E in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

The Alzheimer beta-amyloid protein precursor/protease nexin-II is cleaved by secretase in a trans-Golgi secretory compartment in human neuroglioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

beta-Amyloid efflux mediated by p-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Targeting the Nogo receptor to treat central nervous system injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

The role of intracellular amyloid beta in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer's transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Gene dosage of the amyloid beta precursor protein in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Mutant genes in familial Alzheimer's disease and transgenic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Clearance of amyloid-beta by circulating lipoprotein receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Cellular mechanisms of beta-amyloid production and secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Variable phenotype of Alzheimer's disease with spastic paraparesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Novel modulators of amyloid-beta precursor protein processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Bapineuzumab in Alzheimer's disease: where now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

New therapeutic targets in the neurovascular pathway in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain barrier of an in situ perfused guinea-pig brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Kinetics of arginine-vasopressin uptake at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1073858410381532

21 January 2018

Identifiers

DOI

10.1177/1073858410381532

1 reference

24 August 2017

1 reference